基于miR21的宫颈癌细胞顺铂敏感性机制研究

摘要
图/表
参考文献(19)
相关文章 (2)

全文: PDF (1308 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨miR21影响宫颈癌细胞株Hela及顺铂耐药细胞株Hela/DDP顺铂敏感性的分子机制。方法利用riboFECTTM CP转染试剂分别将成熟miR21 mimic及其阴性对照试剂NC转染至Hela细胞，miR21 inhibitor及其阴性对照试剂NC转染至Hela/DDP细胞，并将细胞分为mimic组、inhibitor组、相应NC组及Blank组。Real-time PCR检测PTEN mRNA的表达水平；流式细胞仪检测细胞周期（PI法）及经顺铂处理后的凋亡率（AnnexinⅤ/PI法）。结果 Real-time PCR法检测PTEN mRNA在Hela/DDP中低表达，为Hela的（0.410±0.046）倍（P ＜ 0.01）；转染mimic后，Hela中PTEN mRNA表达明显低于NC组及Blank组（P ＜ 0.01），NC组与Blank组比较差异无统计学意义（P ＞ 0.05）；转染inhibitor后，Hela/DDP中miR21表达明显高于NC组及Blank组（P ＜ 0.01），NC组与Blank组比较差异无统计学意义（P ＞ 0.05）。AnnexinⅤ/PI检测结果显示，mimic组凋亡率与NC组、Blank组比较明显减少（P ＜ 0.05），inhibitor组凋亡率与NC组、Blank组比较显著提高（P ＜ 0.05）。PI法检测结果显示，mimic组S期所占比例与NC组、Blank组比较明显增加（P ＜ 0.05），NC组与Blank组比较差异无统计学意义（P ＞ 0.05）；inhibitor组S期所占比例与NC组、Blank组比较明显减少（P ＜ 0.05），NC组与Blank组比较差异无统计学意义（P ＞ 0.05）。结论 PTEN mRNA在Hela/DDP中低表达，在Hela中高表达。上调miR21在Hela中的表达能明显降低PTEN mRNA的表达，减少凋亡，增加细胞周期中S期所占比例，导致细胞耐药；下调miR21在Hela/DDP中的表达能明显增加PTEN mRNA的表达，增加凋亡率，降低细胞周期中S期所占比例，从而达到增加化疗敏感性的效果。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	岳晓雪苗劲蔚路攀

关键词 ：宫颈癌细胞, 宫颈癌顺铂耐药细胞, miR21, PTEN, 顺铂, 化疗敏感性

Abstract：Objective To detect the mechanism of miR21 gene on the sensitivity of Hela and Cisplatin-resistant Hela/DDP cells to Cisplatin. Methods Mature miR21 mimic and negative control (NC) miRNA were transfected into Hela cells, while miR21 inhibitor and negative control (NC) miRNA were transfected into Hela/DDP cells by riboFECTTM CP. Therefore, Hela cells were divided into mimic group, inhibitor group, NC group and blank group. Real-time PCR was used to measure the expression of PTEN mRNA in each group. The cell cycle was measured through PI method and apoptosis rate of cells after Cisplatin treatment was detected through AnnexinⅤ/PI by fluorescene activated cell sorter. Results Real-time PCR results showed that the expression of PTEN mRNA was an average of (0.410±0.046) fold higher in Hela/DDP than in Hela (P ＜ 0.01). The expression of PTEN mRNA in mimic group was obviously lower than those in NC group and blank group (P ＜ 0.01). The expression of PTEN mRNA in inhibitor group was significantly higher than those in NC group and blank group (P ＜ 0.01). There was no statistical difference between NC group and blank group (P ＞ 0.05) in Hela and Hela/DDP cells. The results of Annexin Ⅴ/PI showed that the apoptosis rate of mimic group was lower than NC group and blank group (P ＜ 0.05), while the inhibitor group showed that the apoptosis rate was more than NC group and blank group (P ＜ 0.05). The of cell proportion of S period in mimic group was higher than those of NC group and blank group (P ＜ 0.05), and there was no significant difference between NC group and blank group (P ＞ 0.05). In the meantime, the cell proportion of S period in inhibitor group was less than those of NC group and blank group (P ＜ 0.05), and there was no significant difference between NC group and blank group (P ＞ 0.05). Conclusion PTEN mRNA is low expressed in Hela/DDP cells and highly expressed in Hela cells. The up-regulated expression of miR21 in Hela can significantly reduce the expression of PTEN mRNA, reduce apoptosis and increase the proportion of S phase in the cell cycle, thereby resulting in Cisplatin resistance. The down-regulated expression of miR21 in Hela/DDP can increase the expression of PTEN mRNA, increase the apoptosis rate and reduce the proportion of S phase in the cell cycle, so as to increase the chemosensitivity of Cisplatin.

Key words： Hela Hela/DDP miR21 PTEN Cisplatin Cheosensitivity

基金资助:首都医科大学基础-临床科研合作基金项目（2016-JL-PT-Y02）；
北京市科学技术委员会重点项目（D131100005313009）。

通讯作者: 苗劲蔚（1968.6-），女，博士，主任医师；研究方向：妇科肿瘤。

作者简介: 岳晓雪（1993.8-），女，首都医科大学2016级妇产科学专业在读硕士研究生；研究方向：妇科肿瘤微创临床、基础研究。

引用本文:

岳晓雪苗劲蔚路攀. 基于miR21的宫颈癌细胞顺铂敏感性机制研究[J]. 中国医药导报, 2018, 15(6): 13-18.
YUE Xiaoxue MIAO Jinwei LU Pan. Study on the mechanism of Cisplatin chemosensitivity in cervical cancer cells based on miR21. 中国医药导报, 2018, 15(6): 13-18.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I6/13

[1] 杨朝晖，章辉，顾华敏，等.宫颈癌组织中miR-21和Stat3的表达及相关性研究[J].浙江医学，2017，39（2）：93-96.
[2] 沈源明.MiR-375参与宫颈癌泰素敏感性调节的机制研究[D].杭州：浙江大学，2012.
[3] Tian L，Zhang J，Ren X，et al. Overexpression of miR-26b decreases thecisplatin-resistance in laryngeal cancer by targeting ATF2 [J]. Oncotarget，2017，8（45）：79 023-79 033.
[4] Lu C，Xie Z，Peng Q. MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer [J]. Am J Cancer Res，2017， 7（9）：1863-1873.
[5] Au Yeung CL，Co NN，Tsuruga T，et al. Exosomal transfer of stroma-derived miR21 conferspaclitaxel resistance in ovarian cancer cells through targeting APAF1 [J]. Nat Commun，2016，7：11150.
[6] Giunti L，da Ros M，Vinci S，et al. Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis [J]. Am J Cancer Res，2014，5（1）：231-242.
[7] 岳晓雪，苗劲蔚，路攀.miR21对宫颈癌Hela细胞及顺铂耐药Hela/DDP细胞顺铂敏感性的影响[J].中国医药导报，2017，14（36）：25-28.
[8] Du G，Cao D，Meng L. miR-21 inhibitor suppresses cell proliferation and colonyformation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells [J]. Mol Med Rep，2017，15（5）：2713-2719.
[9] Dong Z，Ren L，Lin L，et al. Effectof microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells [J]. Mol Med Rep，2015，11：682-690.
[10] Khella HW，White NM，Faragalla H，et al. Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses [J]. Tumor Biol，2012，33（1）：131-140.
[11] Rui M，Qu Y，Gao T，et al. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells [J]. Int J Nanomedicine，2016，12：217-237.
[12] Mohamad M，Wahab NA，Yunus R，et al. Roles of MicroRNA21 and MicroRNA29a in Regulating Cell Adhesion Related Genes in Bone Metastasis Secondary to Prostate Cancer [J]. Asian Pac J Cancer Prev，2016，17（7）：3437-3445.
[13] Pan Y，Meng M，Zhang G，et al. Oncogenic microRNAs in the genesis of leukemia and lymphoma [J]. Curr Pharm Des，2014，20（33）：5260-5267.
[14] Zheng Z，Xu PP，Wang L，et al. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells [J]. Exp Clin Cancer Res，2017，36（1）：82.
[15] Bertino JR，Banerjee D，Mishra PJ. Pharmacogenomics of microRNA：amiRSN Ptowards individualized therapy [J]. Pharmacogenomics，2007，8（12）：1625-1627.
[16] Chan JK，Blansit K，Kiet T，et al. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer [J]. Gynecol Oncol，2014，132：739-744.
[17] Tao J，Lu Q，Wu D，et al. microRNA-21 modulatescell proliferation and sensitivity to doxorubicinin bladder cancer cells [J]. Oncol Rep，2011，25：1721-1729.
[18] Wang T，Cai Z，Hong G，et al. MicroRNA-21 increases cell viability and suppresses cellular apoptosis in nonsmall cell lung cancer by regulating the PI3K/Akt signaling pathway [J]. Mol Med Rep，2017，16（5）：6506-6511.
[19] Wu WS，Tu BW，Chen TT，et al. CSmiRTar：Condition-Specific microRNA targets database [J]. PLoS One，2017， 12（7）：e0181231.